Transcript Investor Pitch Deck Template

Investment Pitch Deck
Your chance to
Invest in Future Medicines
Cannabis a growing trend
Around the world Cannabis is being given serious considerations for its
possible use in the medicine industry.
Isreal now runs a fully functioning medical research facility specializing
in cannabis plant materials for medical supply.
Canada, the USA, and Uruguay are among the world's leaders in
allowing the supply of cannabis product for people suffering from
ailments in which the use of cannabis is supported.
Green Pharma BioTech NZ proposes to take this growth one step
further by producing pure organic cannabis strains that are patentable.
Patentable Product
Green Pharma BioTech will produce in its first year a patentable
strain of cannabis plant and in the following 3 years produce 2
more such patents.
The benefits of owning patents for plant strains allows us to
approach pharmaceuticals with a product that is guaranteed as




chemical free
proven THC % levels
proven CBD % levels
and suitable for children's medicine
Market Reach
• Supply product to pharmaceuticals internationally
• Supply product to dispensaries internationally
• Supply seeds to seed banks
• Supply product to universities and medical research facilities both
internationally and locally
• And supply local doctors with product for test cases
Index
1)
2)
3)
4)
5)
6)
7)
8)
9)
10)
11)
Vision
Momentum, Traction, Expertise
Market Opportunity
Problem & Current Solutions
Product & Service
Business Model
Market Approach & Strategy
Team & Key Stakeholders
Financials
Competition
Investment
Company Vision
Our tongue in cheek motto is easily understood by all
and reflects our focus on health and family happiness:
“We supply Kiwi Buds for Global Happiness”
Traction
August 2014:
Our CEO penned the NZ Govt. Policy for Cannabis Health Law
Reforms.
Core team were assembled.
Expert grower signed on.
September 2014:
Farm 17 years registered as organic acquired.
Lawyer signed on.
Research on plant strains and patentable plant varieties started.
New buildings for the farm researched.
October 2014:
Our CEO and Managing Director work full time for company.
Company registration started.
Funding sought.
Market Opportunity
Our projected market is a niche market supplying
cannabis for medicinal use to;






Pharmaceuticals
Doctors
Labs
Dispensaries
Drug Stores/Chemists/Pharamcies
and other BioTechs
And we want to achieve full global coverage and
product placement.
The Problem
Lack of scientifically proven reputably produced medical
cannabis strains for the global market.
Current Solutions
Other than a few universities and small private
enterprises Israel is the world leader and the only
reputable supplier of medical cannabis products.
Our Solution
To move into the global market with a far superior product
and one that will be adopted by leading pharmaceuticals.
Product / Service
As a global supplier Green Pharma BioTech Ltd will
supply its product to other companies and we will
control that release through approved sellers and
distributors only.
We aim to produce only high end product that will be
sold at premium prices at dispensaries, however for
pharmaceuticals we aim to be a cost effective
solution for bulk supply of the product.
Revenue Model
Our Model:
Low company costs, high priced end product, lead supplier
to a demanding emerging market.
Although as an investor you are expecting a long winded
detailed “revenue model” and we would love to provide if
such existed for this type of industry.
We are simply growing and breeding plants for supply.
Revenue is based on sales from seeds and plant products to
buyers of the medicine cannabis arena.
Marketing & Growth Strategy
Our product by way of much research and development
will be the only patented product available for supply to
the market.
It will also be the only proven 100% Organically Grown
product safe for inclusion in both child and adult
medicines.
We plan to and with great confidence hope to
monopolize the market because it is still very much a
virgin market.
Team
Grant Keinzley, CEO: ex Politician and Humanitarian.
Rob Stewart, Managing Director: Public Servant and
Manager
Rosie Purchas, Director: Human Rights Law Activist
and Lawyer
Tipene Butter Master Grower: Horticulturalist and
experienced Medical Cannabis plant breeder.
Financials
From start up to the end of the third year most of the company's activities are
growing, plant breeding, and patent plant strain development.
From the first year sales revenue comes from supplying seeds to global seed
banks.
It is expected that by the end of the third year that full product supply to
pharmaceuticals will have begun and from this point on the company moves into
a virgin billion dollar industry.
Our conservative & safe 3 year financial plan (we expect to make a lot more
than this).
Setup, Running Costs, & Overheads
Sales Profits
Market Penetration
Year 1
$661,200
$400,000
5~10%
Year 2
$470,800
$1,600,000
30%
Year 3
$470,800
$1,200,000
45%
Competition
In the global marketplace there is only one serious competitor;
that being the Medical Cannabis Research Center in Isreal.
Our market advantage is our focus on producing 100% organic
product and that our product is precise in its engineering.
Our plant strains' core elements THC & CBD are incrementally
measured as;


.1% CBD
.2% CBD
versus present medicinal use supplies measuring in at;


1.0% CBD
2.0% CBD
This makes our product superior and more suitable for medical
applications.
Investment
We are seeking NZ$3,000,000 equaling 25% o the
company as seed capital to implement the full launch of the
company.
The seed capital covers 5 years of the company's running
costs, staff costs, infrastructure costs, and some buildings
constructed on the property.
The return on investment will be in dividends based on
profit and share value.
We offer all interested investors a personalised investment
portfolio. $3million is a lot but if you have $30,000 you can
still take a piece of the pie, Give us a call.
Final Note & Thanks
Because of the nature of this enterprise; growing and breeding plants
for patenting, simply said “its not rocket science”
Why we will dominate the market is because we will be distributing
proven quality assured medical use product that with the employ of an
international distribution and sales company will flood the market and
make our brand the only brand.
We at Green Pharma BioTech thank you for your consideration and
time and look forward to doing business with you.
Grant Keinzley, CEO of Green Pharma BioTech